Central Nervous System Therapeutics Market Size - By Disease (Degenerative, Mental health, Neurovascular, Infectious), Drug type (Antidepressant, Immunomodulatory drug, Anti-epileptics), Distribution Channel, Global Forecast (2023 – 2032)

Central Nervous System Therapeutics Market Size

Central Nervous System Therapeutics Market size was anticipated to be worth USD 110.4 billion in 2022 and is expected to reach USD 238.8 billion by 2032, increasing at an 8% CAGR 2032. The rising prevalence of CNS disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and depression drives the demand for effective CNS therapeutics.
 

Moreover, technological advancements in treatment approaches,  increasing adoption of novel drug delivery systems, neuromodulation techniques, and personalized medicine. These advancements allow for more precise and effective drug delivery to the CNS, enhancing therapeutic outcomes and minimizing side effects.
 

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the central nervous system therapeutics market. The pandemic has led to a decrease in the number of patients being treated for CNS disorders, as well as a decrease in the number of new CNS drug approvals.
 

The healthcare system was overwhelmed by the unpredicted demand of managing COVID-19 patients, leading to a shift in priorities and resources. Elective procedures, including those related to CNS disorders, were postponed in 2020. Many people have been reluctant to go to the doctor during the pandemic, for fear of contracting COVID-19. This has led to a decrease in the number of patients being diagnosed with CNS disorders, as well as a decrease in the number of patients being treated for these disorders.
 

Moreover, the pandemic disrupted ongoing clinical trials and research activities related to CNS therapeutics. Many trials were halted or postponed due to restrictions on patient recruitment, limited access to healthcare facilities, and prioritization of COVID-19 research. This led to delays in the development and regulatory approval of new CNS therapies.
 

However, pandemic resulted in increased stress, anxiety, depression, and other mental health conditions. This created a higher demand for CNS therapeutics related to mental health disorders. Telemedicine and virtual care solutions were utilized to provide remote mental health support and prescriptions for CNS medications. This shift is expected to have long-term implications for the delivery of CNS therapies.
 

Central Nervous System Therapeutics Market Trends

The market is experiencing several notable trends that are shaping its progression and development. Some key trends in the industry includes increasing advancements in precision medicine, increasing focus on developing therapeutics that not only alleviate symptoms but also target the underlying mechanisms of CNS disorders, rise of digital therapeutics and remote monitoring, integration of artificial intelligence in healthcare, and focus on combination therapies.
 

Central Nervous System Therapeutics Market Analysis

Based on disease, the central nervous system therapeutics market is segmented as degenerative disorders, mental health, neurovascular diseases, autoimmune and inflammatory diseases, infectious diseases, CNS cancer, genetic diseases, CNS trauma, substance abuse disorders, and other diseases. In 2022, the degenerative disorders segment accounted for the largest share of 37.7% in industry. Degenerative disorders such as alzheimer's disease, parkinson's disease, and huntington's disease are often associated with aging. As the global population continues to age, the prevalence of these disorders is increasing.

Based on drug type, the central nervous system therapeutics market is segmented as antidepressant, immunomodulatory drug, anti-epileptics, analgesics, anti-parkinson drugs, anesthetics, decarboxylase inhibitors, dopamine agonists, interferons, and other drug classes. The antidepressant segment held dominant market share of around 25.5% in 2022 and is expected to grow at a significant pace of 8.3% by 2032. The increasing prevalence of mental health disorders such as depression, anxiety, increased awareness and diagnosis about these diseases, improved access to mental health services, and effectiveness and efficacy of antidepressants in the management of various CNS disorders.
 

The pharmaceutical industry has made significant advancements in the development of antidepressant drugs. Newer classes of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants, offer improved efficacy and tolerability profiles compared to older generations of medications.
 

Based on distribution channel, the central nervous system therapeutics market is segmented as hospital pharmacies, retail pharmacies, and other distribution channels. The hospital pharmacies segment held a dominant market share of 48.6% in 2022 and is expected to grow at a CAGR of 7.9% by 2032. Hospitals serve as a primary care setting for patients with acute and severe CNS conditions, such as strokes, traumatic brain injuries, seizures, and psychiatric emergencies.
 

North America central nervous system therapeutics market is expected to reach USD 113.3 billion in 2032 with a CAGR of 7.9% by 2032. North America experiences a substantial burden of CNS disorders, including neurodegenerative diseases, mental health disorders, epilepsy, and multiple sclerosis. The prevalence of these conditions drives the demand for effective CNS therapeutics.
 

Moreover, the region's focus on technological advancements in healthcare contributes to the development of innovative CNS therapeutics. North America is at the forefront of research and development in areas such as precision medicine, gene therapy, digital health, and neuroimaging.
 

Central Nervous System Therapeutics Market Share

Some of the major market players operating in the central nervous system therapeutics market are

• Biogen
• Otsuka Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• Merck & Co.
• Astra Zeneca
• Shire PLC
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• Pfizer, Inc.
   

Central Nervous System Therapeutics Industry News:

• In January 2023, Biogen Inc. and Alcyone Therapeutics have agreed to collaborate and licence Alcyone's ThecaFlex DRx System, an implanted medical device designed for subcutaneous administration of antisense oligonucleotide (ASO) medicines into the intrathecal region. Biogen intends to use the ThecaFlex DRx System to improve the patient treatment experience and accessibility for a broader population of people suffering from neurological disorders such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) through this agreement.
   
• In January 2022, Acadia Pharmaceuticals Inc. and Stoke Therapeutics Inc. announced a partnership to study, develop, and commercialize new RNA-based therapeutics for the potential treatment of severe and rare genetic neurodevelopmental central nervous system (CNS) diseases. SYNGAP1 syndrome, Rett syndrome (MECP2), and an unidentified neurodevelopmental target of common interest are all part of the cooperation.
   

The central nervous system therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Disease, 2018 - 2032 (USD Million)

• Neurovascular diseases
• Mental health
  • Anxiety disorders
  • Mood disorders
  • Epilepsy
  • Psychotic disorders
  • Other mental health disorders
• Degenerative disorders
  • Alzheimer’s disease
  • Parkinson’s disease
  • Multiple sclerosis
  • Huntington's disease
  • Amyotrophic lateral sclerosis
  • Other degenerative disorders
• Genetic diseases
• Substance abuse disorders
• Autoimmune and inflammatory diseases
• CNS trauma
• Infectious diseases
• CNS cancer
• Other diseases

By Drug type, 2018 - 2032 (USD Million)

• Analgesics
• Antidepressant 
• Anesthetics
• Anti-parkinson drugs
• Anti-epileptics
• Decarboxylase inhibitors
• Dopamine agonists
• Immunomodulatory drug
• Interferons
• Other drug classes

By Distribution Channel, 2018 - 2032 (USD Million)

• Hospital pharmacies
• Retail pharmacies
• Other distribution channels

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa